Dueling Over Executive Compensation
This article was originally published in Start Up
Executive Summary
Executive compensation plays a big part in recruiting and retaining excellent executives. But it's not easy. VCs and corporate boards assembling compensation packages wrestle with many matters, including when, how and for what to award bonuses. How to assign stock options and set exercise prices? And are the complications of employee participation incentive plans worth while? Matters of compensation are often neglected until a crisis occurs, but they shouldn't be.
You may also be interested in...
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Why Investors Adopt Orphans
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?
Can Anyone Make Money from Biomarkers?
Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.